---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-002655"
form_type: "8-K"
ticker: "RARE"
cik: "0001515673"
company_name: "Ultragenyx Pharmaceutical Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:13:57.872238+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Ultragenyx reports preliminary 2023 revenue $430-435M; guides 2024 revenue $500-530M

## Summary
- Preliminary 2023 total revenue $430-435M; Crysvita $325-330M, Dojolvi $70-71M.
- 2024 total revenue guidance $500-530M; Crysvita $375-400M, Dojolvi $75-80M.
- Year-end 2023 cash ~$776M; 2024 net cash used in ops guided <$400M.
- Phase 3 data readouts expected H1 2024 for GSDIa gene therapy (DTX401) and OI study enrollment completion.

## SEC filing metadata
- accession: 0000950170-24-002655
- form_type: 8-K
- ticker: RARE
- cik: 0001515673
- company_name: Ultragenyx Pharmaceutical Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1515673/000095017024002655/0000950170-24-002655-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1515673/000095017024002655/rare-20240107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-002655
- JSON: https://secwatch.observer/filing/0000950170-24-002655.json
- Plain text: https://secwatch.observer/filing/0000950170-24-002655.txt

## Key facts
- Earnings Releases
  Ultragenyx Pharmaceutical Inc. reported fiscal year 2024 results: revenue $500 million to $530 million. Guidance initiated.
  - Period: fiscal year 2024
  - Revenue: $500 million to $530 million
  - Guidance: initiated
  - Result: guidance update
  source text: 2024 expected Total Revenue guidance between $500 million to $530 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017024002655/0000950170-24-002655-index.htm
- Earnings Releases
  Ultragenyx Pharmaceutical Inc. reported fiscal year 2023 results: revenue $430 million to $435 million.
  - Period: fiscal year 2023
  - Revenue: $430 million to $435 million
  - Result: preliminary results
  source text: Preliminary 2023 Total Revenue of $430 million to $435 million, Crysvita® Revenue of $ 325 million to $330 million and Dojolvi® revenue of $70 million to $71 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1515673/000095017024002655/0000950170-24-002655-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.